Bob Duggan, Summit Therapeutics co-CEO
December 6, 2022 11:41 AM ESTUpdated December 7, 12:45 PM
Financing
Deals

Bounc­ing from ma­jor set­back, Sum­mit hands out $500M cash for can­cer drug — thanks to a loan from bil­lion­aire CEO

Amber Tong

Af­ter hit­ting a dead end with Sum­mit Ther­a­peu­tics’ lead pro­gram, Bob Dug­gan has found the drug that he be­lieves will ush­er in­to a com­pelling sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

A service from the Financial Times